viewAIM ImmunoTech Inc.

Hemispherx Biopharma shares soar as reverse split takes effect

The biopharma is looking to strengthen its position as it moves forward with several studies of its flagship drug, ampligen

stock arrow rising
The 1-for-44 split has propelled the shares above the company's $5 target

Shares of Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) were up sharply Tuesday in their first day of trading after a 1-for-44 reverse stock split.

The Florida-based company announced the move on May 31, anticipating that a split could help propel the stock to $5 per share.

That goal was reached — and then some — with the stock rising about 16% to $5.20 in afternoon trading on the NYSE American.

READ: Hemispherx Biopharma board approves 1-for-44 reverse stock split

The biopharma is looking to strengthen its position as it moves forward with several studies of its flagship drug, ampligen, which the company says has shown progress in the treatment of breast and prostate cancers.

“We want a stock price high enough to allow all major players in the market, such as well-established funds, family offices, banks and index funds to buy on the open market and create favorable buying pressure on the stock,” said CEO Thomas Equels.

Contact Paul Curcio at [email protected]

Follow him on Twitter @GoCurcioGo

Quick facts: AIM ImmunoTech Inc.

Price: 0.5753 USD

Market: NYSE
Market Cap: $2.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...



Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read